Publications

Filter Publications By:

Selumetinib / Cancer

09/28/2014

ESMO

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Encorafenib / Cancer

09/26/2014

ESMO Congress 2014 - Madrid, Spain

Ph Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF‐mutant melanoma

M. H. Taylor, et. al

Encorafenib / Cancer

09/26/2014

ESMO Annual Meeting - Madrid, Spain

Encorafenib (LGX818), an Oral BRAF Inhibitor, in Patients With BRAF V600E Metastatic Colorectal Cancer: Results of Dose Expansion in an Open-Label, Phase 1 Study

C. Gomez-Roca, et. al

Filanesib / Multiple Myeloma

06/13/2014

European Hematology Association

Phase 1 Study of Filanesib (ARRY-520) with Bortezomib (BTZ) and Dexamethasone (dex) in Relapsed or Refractory Multiple Myeloma (RRMM)

A. Chari, et al.

Selumetinib / Cancer

06/02/2014

American Society of Clinical Oncology Meeting

A Phase I Study of the MEK1 Inhibitor Selumetinib (AZD6244) Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PNs)

B. C. Widemann, et al.

Binimetinib / Cancer

06/01/2014

American Society of Clinical Oncology Meeting

A Phase 1b/2 Study of LEE011 in Combination With Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma: Early Encouraging Clinical Activity

J. A. Sosman, et al.

Binimetinib / Cancer

05/31/2014

American Society of Clinical Oncology Meeting

A Phase 1b Open-Label, Multicenter, Dose-Escalation and -Expansion Study of Orally Administered Binimetinib (MEK162) Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

D. Juric, et al.

Binimetinib / Cancer

05/31/2014

American Society of Clinical Oncology Meeting

A Multinational, Randomized, Open-label Phase 3 Study of Binimetinib (MEK162) versus Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

B. J. Monk, et al.

Binimetinib / Cancer

05/30/2014

American Society of Clinical Oncology Meeting

A Phase II Cluster Study of Single-agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

Q. Zhou, et. al

Encorafenib / Cancer

04/11/2014

HemOnc Today: Melanoma and Cutaneous Malignancies, April 11-12, 2014, New York, NY

The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma

R. Dummer, et. al